title: [First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of capecitabine as first-line therapy in patients with advanced and recurrent colorectal cancer.
  
  
  METHODS
  From December 2000 to November 2001, sixty patients with advanced and recurrent colorectal cancer received first-line capecitabine treatment given at a dose of 1250 mg/m(2) twice daily, on days 1 - 14 every 21 days. At least 2 cycles were administered.
  
  
  RESULTS
  The overall response rate was 23.3% with 14 PR, 24 SD (40.0%) and 15 PD. The median survival time was 14.7 months. The survival rate was 63.9% at 12-months and 33.4% at 24-months. Grade III-IV adverse effects were diarrhea in 4 patients (6.6%), anemia in 2 (3.3%) and hand-foot syndrome (HFS) in 1 (1.7%); Grade I-II adverse effects were hyperpigmentation in 20 (33.3%), HFS in 18 (30.0%) and diarrhea in 10 (16.7%).
  
  
  CONCLUSIONS
  Capecitabine is an efficacious and better-tolerated alternative treatment for the patients with advanced and recurrent colorectal cancer.
authors.affiliation: Department of Internal Medicine of Cancer Center, Sun Yat-sen University of Medical Sciences, Guangzhou 510060, China. zzguan@21cn.com
authors.forename: Zhong-zhen
authors.initials: ZZ
authors.lastname: Guan
authors.forename: Dong-geng
authors.initials: DG
authors.lastname: Liu
authors.forename: Bao-ming
authors.initials: BM
authors.lastname: Yu
authors.forename: Wei-qin
authors.initials: WQ
authors.lastname: Wu
authors.forename: De
authors.initials: D
authors.lastname: Shi
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhao
authors.forename: Yu-quan
authors.initials: YQ
authors.lastname: Wei
authors.forename: Li-qun
authors.initials: LQ
authors.lastname: Zou
authors.forename: Xiao-ding
authors.initials: XD
authors.lastname: Wu
authors.forename: Wen
authors.initials: W
authors.lastname: Zhuang
authors.forename: Feng-yi
authors.initials: FY
authors.lastname: Feng
authors.forename: Pin
authors.initials: P
authors.lastname: Zhang
authors.forename: Shi-ying
authors.initials: SY
authors.lastname: Yu
authors.forename: Hui-hua
authors.initials: HH
authors.lastname: Xiong
authors.forename: Qiang
authors.initials: Q
authors.lastname: Fu
authors.forename: Shu
authors.initials: S
authors.lastname: Zheng
authors.forename: Jian-jin
authors.initials: JJ
authors.lastname: Huang
authors.forename: Gang
authors.initials: G
authors.lastname: Wu
authors.forename: Chuan-yong
authors.initials: CY
authors.lastname: Yang
authors.forename: Sheng-rong
authors.initials: SR
authors.lastname: Sun
authors.forename: Qing-lan
authors.initials: QL
authors.lastname: Ruan
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil